AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) A method of isolating plasma from a canine animal including the steps of:

(I) selecting a donor canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group;

(II) collecting blood from the canine animal; and

(III) isolating plasma from blood collected in step (II).

2. (original) The method of claim 1 wherein the canine animal is selected for a phenotype lacking at least one Dog Erythrocyte Antigen.

3. (original) The method of claim 2 wherein the canine animal is negative for Dog Erythrocyte Antigen 1.1.

4. (original) The method of claim 3 wherein the canine animal is negative for Dog Erythrocyte Antigen 1.2.

5. (original) The method of claim 4 wherein the canine animal is negative for Dog Erythrocyte Antigen 7.

6. (currently amended) The method of ~~any one of~~ claim~~s~~ 1 ~~to 5~~ wherein the canine animal is selected for a phenotype lacking anti-globulin antibodies.

7. (original) The method of claim 1 further including the steps of:

(a) inserting a blood collecting catheter into a vein of the canine animal;

(b) attaching the blood collecting catheter to a cell separator capable of separating blood into an isolated plasma component and an isolated blood cell component;

(c) collecting blood from the canine animal via the blood collection catheter;

(d) separating the blood into the isolated plasma component and the isolated blood cell component;

(e) collecting the isolated plasma component;

(f) stopping the collecting of blood;

(g) returning the blood cell component to the canine animal; and

(h) repeating steps (c) – (g).

8-32. (cancelled)

33. (original) A method of producing hyperimmunised canine animal plasma including the steps of:

(1) selecting a canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group;

(2) administering to the canine animal at least one antigen thereby inducing an immune response in said canine animal;

(3) administering to said canine animal at least one same antigen(s) administered in step (2) during said immune response; and

(4) isolating plasma from said canine animal.

34. (original) The method of claim 33 wherein said canine animal is characterised by a phenotype negative for at least one Dog Erythrocyte Antigen.

35. (original) The method of claim 34 wherein said canine animal is characterised by a phenotype negative for Dog Erythrocyte Antigen 1.1.

36. (currently amended) The method of claim ~~35~~ 34 wherein said canine animal is characterised by a phenotype negative for Dog Erythrocyte Antigen 1.2.

37. (currently amended) The method of claim ~~36~~ 34 wherein said canine animal is characterised by a phenotype negative for Dog Erythrocyte Antigen 7.

38. (currently amended) The method of ~~any one of~~ claim~~s~~ 33 ~~to 37~~ wherein said canine animal is characterised by a phenotype negative for anti-globulin antibodies.

39-48. (cancelled)

49. (original) The method of claim 33 wherein the antigen(s) are selected from the groups of antigens obtained from: distemper virus, canine adenovirus type 2 (CAV2), canine parvovirus type 2 (CPV2), canine parainfluenza virus, *Bordetella bronchiseptica*, *E. coli*, or respective components thereof.

50. (original) The method of claim 49 wherein the *E. coli* is heat killed.

51. (original) The method of claim 50 wherein the *E. coli* is *E. coli* J5.

52-54. (cancelled)

55. (original) Isolated canine animal plasma comprising at least one immunoglobulin capable of binding to a gram negative bacteria or component thereof.

56. (original) The isolated canine animal plasma of claim 55 wherein said gram negative bacteria or component thereof is *E. coli.*

57. (original) The isolated canine animal plasma of claim 56 wherein the *E. coli* is *E. coli* J5.

58. (currently amended) The isolated canine animal plasma of claim ~~56~~ 57 wherein the component of the *E. coli* is lipopolysaccharide, oligosaccharide and/or a respective component thereof.

59. (currently amended) The isolated canine animal plasma of claim ~~55~~ 58 further comprising at least one immunoglobulin capable of binding an additional canine animal pathogen.

60. (original) The isolated canine animal plasma of claim 59 wherein the canine animal pathogen is selected from the group consisting of: a virus, parasite and bacteria.

61. (original) The isolated canine animal plasma of claim 60 wherein the canine animal pathogen is selected from the group consisting of: distemper virus, canine adenovirus type 2 (CAV2), canine parvovirus type 2 (CPV2), canine parainfluenza virus and *Bordetella bronchiseptica.*

62-66. (cancelled)

67. (currently amended) A method for treating or improving health of a canine animal of a condition including the steps of administering to the canine animal isolated canine animal plasma of ~~any one of~~ claims ~~53 to 66~~ 55.

68. (original) The method of claim 67 wherein said condition is selected from the group consisting of: parvovirus infection, lack of passive transfer of antibodies to a canine pup, hypoprotinaemia, glomerulonepheritis, shock, fluid therapy, congenital clotting disorders, thrombocytopenia, vitamin K deficiency, haemphilia, disseminated intravascular coagulation, pancreatitis, reduced blood coagulation, infection, surgery, tissue injury and destruction, pyometron, poisoning, snake envenomation, advanced blood loss and severely debilitating infections.

69. (original) The method of claim 68 wherein reduced blood coagulation is a result of poisoning, disseminated intravascular coagulation and/or haemophilia.

70. (currently amended) The method of claim ~~67~~ 69 wherein the isolated canine animal plasma is administered in range of 2-15 mL/Kg weight of the canine animal per hour.

71-72. (cancelled)